

ABSTRACT

The present invention relates to novel, soluble, recombinant RANKL (Receptor Activator of Nuclear Factor - κ B Ligand) variant proteins which may be expressed solubly in *E. coli*, variants that have
5 substantially reduced binding to OPG, variants that act as RANKL antagonists, and methods for generating the same.